Kristin Peck

Zoetis was spun off from Pfizer in 2013 and has since established itself as the dominant player in veterinary pharmaceuticals, with leading positions in both companion animal (pets) and livestock health. The companion animal segment has been Zoetis's standout growth driver, fueled by the powerful and seemingly irreversible trend of pet humanization — pet owners increasingly treat their animals as family members and are willing to spend significantly on healthcare. Zoetis's key companion animal products include Simparica Trio (a triple-action parasite protection for dogs), Apoquel and Cytopoint (for atopic dermatitis/allergies), and the breakthrough pain medication Librela (bedinvetmab, a monoclonal antibody for osteoarthritis pain in dogs and now cats) — the first drug of its kind in veterinary medicine. Librela has been a transformational product: it provides monthly pain relief through a simple injection, addressing the massive unmet need for effective, safe pain management in aging pets. The product has launched to strong demand globally and is expected to become a multi-billion-dollar franchise. Key stock drivers include Librela sales trajectory, Simparica franchise growth, livestock segment recovery, overall companion animal spending trends, new product launches, and the competitive dynamics with Elanco, Merck Animal Health, and Boehringer Ingelheim.